RXi Pharmaceuticals announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for both the composition of matter and methods of use for its self-delivering RNAi (sd-rxRNA) compounds targeting connective tissue growth factor (CTGF). The patent also includes the company’s clinical candidate, RXI-109, an sd-rxRNA compound that silences CTGF and is currently being evaluated in Phase 2 clinical trials for the reduction of hypertrophic scars following scar revision surgery.
The patent, once issued, will not expire until 2031.
“We are pleased to have be granted this Notice of Allowance from the USPTO,” said Geert Cauwenbergh, PhD, president and CEO of RXi Pharmaceuticals. “This patent protection for our novel self-delivering RNAi technology further strengthens our position to generate business and commercial development opportunities in the areas of dermal and ocular scarring as well as other fibrotic indications, such as liver fibrosis.”
